174 related articles for article (PubMed ID: 24916692)
1. Increasing stability of antibody via antibody engineering: stability engineering on an anti-hVEGF.
Wang S; Liu M; Zeng D; Qiu W; Ma P; Yu Y; Chang H; Sun Z
Proteins; 2014 Oct; 82(10):2620-30. PubMed ID: 24916692
[TBL] [Abstract][Full Text] [Related]
2. Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces.
Warszawski S; Borenstein Katz A; Lipsh R; Khmelnitsky L; Ben Nissan G; Javitt G; Dym O; Unger T; Knop O; Albeck S; Diskin R; Fass D; Sharon M; Fleishman SJ
PLoS Comput Biol; 2019 Aug; 15(8):e1007207. PubMed ID: 31442220
[TBL] [Abstract][Full Text] [Related]
3. Antibody affinity maturation in vitro using unconjugated peptide antigen.
Iwai H; Oztürk B; Ihara M; Ueda H
Protein Eng Des Sel; 2010 Apr; 23(4):185-93. PubMed ID: 20123883
[TBL] [Abstract][Full Text] [Related]
4. Influence of canonical structure determining residues on antibody affinity and stability.
Clark LA; Demarest SJ; Eldredge J; Jarpe MB; Li Y; Simon K; van Vlijmen HW
J Struct Biol; 2014 Feb; 185(2):223-7. PubMed ID: 23994046
[TBL] [Abstract][Full Text] [Related]
5. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
[TBL] [Abstract][Full Text] [Related]
6. Control of IgG LC:HC ratio in stably transfected CHO cells and study of the impact on expression, aggregation, glycosylation and conformational stability.
Ho SC; Koh EY; van Beers M; Mueller M; Wan C; Teo G; Song Z; Tong YW; Bardor M; Yang Y
J Biotechnol; 2013 Jun; 165(3-4):157-66. PubMed ID: 23583871
[TBL] [Abstract][Full Text] [Related]
7. Critical interactions in binding antibody NC41 to influenza N9 neuraminidase: amino acid contacts on the antibody heavy chain.
Pruett PS; Air GM
Biochemistry; 1998 Jul; 37(30):10660-70. PubMed ID: 9692956
[TBL] [Abstract][Full Text] [Related]
8. [Recombinant design and expression of human three-domain antibody against BoNTa].
Wang H; Yin J; Shi J; Meng LL; Li PZ
Wei Sheng Wu Xue Bao; 2005 Apr; 45(2):223-5. PubMed ID: 15989265
[TBL] [Abstract][Full Text] [Related]
9. Fabs specific for 8-oxoguanine: control of DNA binding.
Bespalov IA; Bond JP; Purmal AA; Wallace SS; Melamede RJ
J Mol Biol; 1999 Nov; 293(5):1085-95. PubMed ID: 10547287
[TBL] [Abstract][Full Text] [Related]
10. Structure-based engineering of a monoclonal antibody for improved solubility.
Wu SJ; Luo J; O'Neil KT; Kang J; Lacy ER; Canziani G; Baker A; Huang M; Tang QM; Raju TS; Jacobs SA; Teplyakov A; Gilliland GL; Feng Y
Protein Eng Des Sel; 2010 Aug; 23(8):643-51. PubMed ID: 20543007
[TBL] [Abstract][Full Text] [Related]
11. A mutational analysis of the binding of two different proteins to the same antibody.
Dall'Acqua W; Goldman ER; Eisenstein E; Mariuzza RA
Biochemistry; 1996 Jul; 35(30):9667-76. PubMed ID: 8703938
[TBL] [Abstract][Full Text] [Related]
12. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability.
Wörn A; Plückthun A
Biochemistry; 1998 Sep; 37(38):13120-7. PubMed ID: 9748318
[TBL] [Abstract][Full Text] [Related]
13. Resolving self-association of a therapeutic antibody by formulation optimization and molecular approaches.
Casaz P; Boucher E; Wollacott R; Pierce BG; Rivera R; Sedic M; Ozturk S; Thomas WD; Wang Y
MAbs; 2014; 6(6):1533-9. PubMed ID: 25484044
[TBL] [Abstract][Full Text] [Related]
14. An integrated approach to extreme thermostabilization and affinity maturation of an antibody.
McConnell AD; Spasojevich V; Macomber JL; Krapf IP; Chen A; Sheffer JC; Berkebile A; Horlick RA; Neben S; King DJ; Bowers PM
Protein Eng Des Sel; 2013 Feb; 26(2):151-64. PubMed ID: 23173178
[TBL] [Abstract][Full Text] [Related]
15. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
[TBL] [Abstract][Full Text] [Related]
16. A new approach to produce IgG
Zhao C; Zhang W; Gong G; Xie L; Wang MW; Hu Y
Sci Rep; 2021 Sep; 11(1):18630. PubMed ID: 34545109
[TBL] [Abstract][Full Text] [Related]
17. Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency.
Tan PH; Sandmaier BM; Stayton PS
Biophys J; 1998 Sep; 75(3):1473-82. PubMed ID: 9726949
[TBL] [Abstract][Full Text] [Related]
18. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
19. Cloning of recombinant monoclonal antibodies from hybridomas in a single mammalian expression plasmid.
Müller-Sienerth N; Crosnier C; Wright GJ; Staudt N
Methods Mol Biol; 2014; 1131():229-40. PubMed ID: 24515469
[TBL] [Abstract][Full Text] [Related]
20. Improving the stability of an antibody variable fragment by a combination of knowledge-based approaches: validation and mechanisms.
Monsellier E; Bedouelle H
J Mol Biol; 2006 Sep; 362(3):580-93. PubMed ID: 16926023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
